Reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age

Vergara, Rodrigo; Tregnaghi, Miguel; Ussher, José; Navarro, Sofía; Rüttimann, Ricardo; Potı́n, Marcela; Wolter, Joanne; Schuerman, Lode

doi:10.1007/s00431-005-1650-y

Cited by 28 publications

(15 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is in accordance with previous studies using a reduced-antigen-content vaccine, even though the vaccine schedules and age groups were somewhat different (38,39,43). There was no significant IgA response to PT; however, two participants had a PT-IgA response (more than 2-fold increase) (30).…”

Section: Discussionsupporting

confidence: 90%

Immunization of Teenagers with a Fifth Dose of Reduced DTaP-IPV Induces High Levels of Pertussis Antibodies with a Significant Increase in Opsonophagocytic Activity

Aase¹,

Herstad²,

Merino³

et al. 2011

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

Waning vaccine-induced immunity against Bordetella pertussis is observed among adolescents and adults. A high incidence of pertussis has been reported in this population, which serves as a reservoir for B. pertussis. A fifth dose of reduced antigen of diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine was given as a booster dose to healthy teenagers. The antibody activity against B. pertussis antigens was measured prior to and 4 to 8 weeks after the booster by different assays: enzyme-linked immunosorbent assays (ELISAs) of IgG and IgA against pertussis toxin (PT) and filamentous hemagglutinin (FHA), IgG against pertactin (PRN), opsonophagocytic activity (OPA), and IgG binding to live B. pertussis. There was a significant increase in the IgG activity against PT, FHA, and PRN following the booster immunization (P < 0.001). The prebooster sera showed a geometric mean OPA titer of 65.1 and IgG binding to live bacteria at a geometric mean concentration of 164.9 arbitrary units (AU)/ml. Following the fifth dose, the OPA increased to a titer of 360.4, and the IgG concentration against live bacteria increased to 833.4 AU/ml (P < 0.001 for both). The correlation analyses between the different assays suggest that antibodies against FHA and PRN contribute the most to the OPA and IgG binding.

show abstract

Section: Discussionsupporting

confidence: 90%

Immunization of Teenagers with a Fifth Dose of Reduced DTaP-IPV Induces High Levels of Pertussis Antibodies with a Significant Increase in Opsonophagocytic Activity

Aase¹,

Herstad²,

Merino³

et al. 2011

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

show abstract

“…The results were consistent with previous reports in adolescents 4,6,14,18 and non-inferiority of the new presentation compared to the old presentation was demonstrated. dTpa administered using the new dTpa syringe presentation was also well tolerated and the incidence and nature of adverse events were similar irrespective of the syringe presentation and comparable with previous studies.…”

Section: Introductionsupporting

confidence: 93%

“…4,5 Boostrix TM , which was first licensed in 1999, is currently available in over 70 countries and has a well-established immunogenicity and tolerability profile in populations ranging from school age to the elderly. [6][7][8][9][10][11][12][13][14][15][16][17][18][19] Traditionally, Boostrix TM has been available as a single-dose vial or a prefilled disposable syringe where the tip-cap and plunger stopper contained methylester W1883. However, following the discontinuation of W1883 production by the manufacturer (West), the syringe presentation has recently been replaced using prefilled syringes from a different manufacturer, wherein the tip-cap component contains FM27 (a latex-free non-cytotoxic rubber compound) and the plunger stopper component contains FM457 (an ultra-low extractable bromobutyl compound).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of a new syringe presentation of reduced-antigen content diphtheria, tetanus, and acellular pertussis vaccine in healthy adolescents - A single blind randomized trial

Pavía-Ruz

Abarca

Lepetic³

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Reduced-antigen-content diphtheria-tetanus-acellular pertussis (dTpa) vaccine, Boostrix TM , is indicated for booster vaccination of children, adolescents and adults. The original prefilled disposable dTpa syringe presentation was recently replaced by another prefilled-syringe presentation with latex-free tip-caps and plunger-stoppers. 671 healthy adolescents aged 10-15 years who had previously received 5 or 6 previous DT(P)/dT(pa) vaccine doses, were randomized (1:1) to receive dTpa booster, injected using the new (dTpa-new) or previous syringe (dTpa-previous) presentations. Immunogenicity was assessed before and 1-month post-booster vaccination; safety/reactogenicity were assessed during 31-days post-vaccination. Non-inferiority of dTpa-new versus dTpa-previous was demonstrated for all antigens (ULs 95% CIs for GMC ratios ranged between 1.03-1.13). 1-month post-booster, immune responses were in similar ranges for all antigens with both syringe presentations. dTpa delivered using either syringe presentation was well-tolerated. These clinical results complement the technical data and support the use of the new syringe presentation to deliver the dTpa vaccine.

show abstract

“…The combined reduced-antigen-content diphtheria, tetanus and acellular pertussis vaccine offers the opportunity to boost older children against recommended antigens, with the potential benefit of reduced reactogenicity compared to full-antigen content vaccines. [17][18][19][20][21][22][23][24] Protection against poliomyelitis has been afforded through administration of live attenuated OPV and IPV. IPV is increasingly preferred over OPV for the fact that it cannot, by its nature, induce vaccine associated paralytic poliomyelitis and that it can be combined with other injectable vaccines into a single vaccine formulation.…”

Section: Discussionmentioning

confidence: 99%

Booster vaccination at 6-8 years of age with a reduced antigen content dTpa-IPV vaccine is immunogenic and safe after priming with whole-cell pertussis vaccine

et al. 2008

View full text Add to dashboard Cite

Pertussis vaccines containing reduced amounts of antigen have been considered primarily for use in adolescents and adults to date. We evaluated a reduced antigen content combined diphtheria tetanus acellular pertussis and inactivated polio vaccine (dTpa-IPV) in 6-8 year-old children in Taiwan, who had received four doses of DTPw (combined diphtheria, tetanus, whole cell pertussis vaccine) and OPV (oral polio vaccine). One month after the booster dose, seroprotection rates and vaccine response rates to all antigens were at least 98.8%, and significant increases in antibody concentrations were observed. Booster vaccination was associated with minor local reactions and systemic symptoms. Symptoms of severe intensity did not occur, with the exception of local pain. The dTpa-IPV vaccine was immunogenic and well tolerated in 6-8 year-old children and offers an alternative to the current use of tetanus and diphtheria vaccine and OPV in Taiwan, addressing the established need for repeated booster vaccinations against pertussis at the same time.

show abstract

Reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age

Abstract: The combined reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and IPV vaccine is immunogenic and well tolerated when administered to adolescents and could be used to improve the control of pertussis disease in this age group.

Cited by 28 publications

References 20 publications

Immunization of Teenagers with a Fifth Dose of Reduced DTaP-IPV Induces High Levels of Pertussis Antibodies with a Significant Increase in Opsonophagocytic Activity

Immunization of Teenagers with a Fifth Dose of Reduced DTaP-IPV Induces High Levels of Pertussis Antibodies with a Significant Increase in Opsonophagocytic Activity

Evaluation of a new syringe presentation of reduced-antigen content diphtheria, tetanus, and acellular pertussis vaccine in healthy adolescents - A single blind randomized trial

Booster vaccination at 6-8 years of age with a reduced antigen content dTpa-IPV vaccine is immunogenic and safe after priming with whole-cell pertussis vaccine

Contact Info

Product

Resources

About